Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04504669CT.gov First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03439085CT.gov DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | — | Terminated | — | — | — |
NCT03518606CT.gov Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | — | Completed | — | — | — |
NCT02725489CT.gov Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | — | Completed | — | — | — |
NCT01975831CT.gov A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Second Affiliated Hospital of Guangzhou Medical University | P2 | B · 59 |
| Vinorelbine Ditartrate | UNICANCER | P2 | BBB |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Uganda Cancer Institute | P3 | B |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | B |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | B |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P3 | B |
| Carboplatin | Merck Sharp & Dohme LLC | P3 | B |
| Indocyanine Green | Istanbul University | P4 | B |
+42 more in the Cervical Cancer cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Cervical Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-cervical-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →